Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lineage Cell Therapeutics Inc (NY: LCTX ) 0.9053 -0.0147 (-1.60%) Official Closing Price Updated: 8:00 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 764,652 Open 0.9204 Bid (Size) 0.8800 (20) Ask (Size) 0.9500 (6) Prev. Close 0.9200 Today's Range 0.8836 - 0.9380 52wk Range 0.7665 - 1.560 Shares Outstanding 174,986,671 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium September 25, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop September 18, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Performance YTD -16.94% -16.94% 1 Month +3.46% +3.46% 3 Month -5.11% -5.11% 6 Month -37.99% -37.99% 1 Year -19.88% -19.88% More News Read More Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference August 13, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 08, 2024 Via InvestorPlace Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 08, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics: Q4 Earnings Insights March 07, 2024 Via Benzinga A Preview Of Lineage Cell Therapeutics's Earnings March 06, 2024 Via Benzinga Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 August 01, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index July 02, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage to Present at 2024 BIO International Convention May 30, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium May 21, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire LCTX Stock Earnings: Lineage Cell Therapeutics Meets EPS, Beats Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 May 02, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit May 06, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) April 30, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Announces Changes to Board of Directors April 29, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development April 01, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023 March 07, 2024 Via InvestorPlace Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium March 18, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 07, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit March 13, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting March 11, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024 February 29, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Earnings Scheduled For March 7, 2024 March 07, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
